Viral Vector Vaccine Development and Application during the COVID-19 Pandemic
Open Access
- 18 July 2022
- journal article
- review article
- Published by MDPI AG in Microorganisms
- Vol. 10 (7), 1450
- https://doi.org/10.3390/microorganisms10071450
Abstract
With the accumulation of mutations in SARS-CoV-2 and the continuous emergence of new variants, the importance of developing safer and effective vaccines has become more prominent in combating the COVID-19 pandemic. Both traditional and genetically engineered vaccines have contributed to the prevention and control of the pandemic. However, in recent years, the trend of vaccination research has gradually transitioned from traditional to genetically engineered vaccines, with the development of viral vector vaccines attracting increasing attention. Viral vector vaccines have several unique advantages compared to other vaccine platforms. The spread of Omicron has also made the development of intranasal viral vector vaccines more urgent, as the infection site of Omicron is more prominent in the upper respiratory tract. Therefore, the present review focuses on the development of viral vector vaccines and their application during the COVID-19 pandemic.Keywords
Funding Information
- the Science and Technology Program of Guangzhou, China (No. 202206010161, No.2019KZDXM026, No.2020B0301030007)
This publication has 72 references indexed in Scilit:
- Multivalent and Multipathogen Viral Vector VaccinesClinical and Vaccine Immunology, 2017
- Nasal Vaccine DeliveryPublished by Elsevier BV ,2016
- Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysScience, 2016
- Upstream Bioprocess for Adenovirus VectorsPublished by Elsevier BV ,2016
- Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialThe Lancet, 2015
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Efficient induction of protective anti-malaria immunity by recombinant adenovirusVaccine, 1998
- The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteersClinical & Experimental Allergy, 1990
- Effects of a "new" human respiratory virus in volunteers.BMJ, 1967